// OVERVIEW
Global pharmaceutical company with major franchises in diabetes, oncology, and immunology.
Discussed in
- Thrive Capital's Bet on Neuralink, OpenAI & the Future of Medicine
- Hyperscalers double-dip the chip
- The hedge fund doubling down on VC
- 3 businesses we think are about to blow up
- We tested Instinct, MUSE and Grokbot. They’re ridiculous.
- Axios Pro Rata_ California clanger — 2026-09-01
- AI's M&A watchlist
- 50 VCs that actually delivered
- 🔥Record Investments, Slowing Economy - Here's the State of the Market in August 2026
- Decacorns are the new unicorns
- 💡 Army of agents
- Biotech IPOs get their groove back
// RECENT MENTIONS
// SIGNALS
39 SIGNALS
01
mention·Dialectic·OCTOBER 15, 2026
Source→02
mention·Sourcery Newsletter·OCTOBER 14, 2026
“Lilly became the first by pairing better science with manufacturing scale during GLP-1 shortages and moving into care delivery with LillyDirect.”
03
m_and_a·Sourcery·OCTOBER 14, 2026
Source→04
AI-extracted from podcast / newsletter / paper summaries. May contain errors.